Cost of antipsychotic polypharmacy in the treatment of schizophrenia

BMC Psychiatry

Volumn 8, Issue , 2008, Pages

  Zhu, Baojin ^a   Ascher Svanum, Haya ^a   Faries, Douglas E ^a   Correll, Christoph U ^b   Kane, John M ^b  

^a ELI LILLY AND COMPANY   (United States)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; DIBENZOTHIAZEPINE DERIVATIVE;

ACCURACY; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; POLYPHARMACY; PRESCRIPTION; SCHIZOPHRENIA; SCORING SYSTEM; TREATMENT OUTCOME; UNITED STATES; COMPARATIVE STUDY; ECONOMICS; MENTAL HEALTH SERVICE; PROSPECTIVE STUDY;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; MENTAL HEALTH SERVICES; POLYPHARMACY; PROSPECTIVE STUDIES; RISPERIDONE; SCHIZOPHRENIA; UNITED STATES;

EID: 43049140470     PISSN: None     EISSN: 1471244X     Source Type: Journal    
DOI: 10.1186/1471-244X-8-19     Document Type: Article

References (33)

1. Lehman AF Lieberman JA Dixon LB McGlashan TH Miller AL Perkins DO Kreyenbuhl J American Psychiatric Association Steering Committee on Practice Guidelines Practice guideline for the treatment of patients with schizophrenia, second edition Am J Psychiatry 2004, 161(2 Suppl 1):56. 15000267
2. Weiden PJ Casey DE "Polypharmacy": Combining antipsychotic medications in the treatment of schizophrenia J Prac Psych and Behav Hlth 1999, 7:229-233.
3. Rittmannsberger H Meise U Schauflinger K Horvath E Donat H Hinterhuber H Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics Eur Psychiatry 1999, 14:33-40. 10.1016/ S0924-9338(99)80713-5 10572323
4. Williams CL Johnstone BM Kesterson JG Javor KA Schmetzer AD Evaluation of antipsychotic and concomitant medication use patterns in patients with schizophrenia Med Care 1999, 37:AS81-AS86. 10.1097/ 00005650-199904001-00011 10217396
5. Miller AL Craig CS Combination antipsychotics: Pros, cons, and questions Schizophr Bull 2002, 28:105-109. 12047009
6. Schumacher JE Makela EH Griffin HR Multiple antipsychotic medication prescribing patterns Ann Pharmacother 2003, 37:951-955. 10.1345/ aph.1C420 12841799
7. Tapp A Wood AE Secrest L Erdmann J Cubberley L Kilzieh N Combination antipsychotic therapy in clinical practice Psychiatr Serv 2003, 54:55-59. 10.1176/appi.ps.54.1.55 12509667
8. Loosbrock DL Zhao Z Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia J Ment Health Policy Econ 2003, 6:67-75. 14578539
9. Ganguly R Kotzan JA Miller LS Kennedy K Martin BC Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000 J Clin Psychiatry 2004, 65:1377-1388. 15491242
10. Procyshyn RM Kennedy NB Tse G Thompson B Antipsychotic polypharmacy: A survey of discharge prescriptions from a tertiary care psychiatric institution Can J Psychiatry 2001, 46:334-339. 11387789
11. Clark RE Bartels SJ Mellman TA Peacock WJ Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy Schizophr Bull 2002, 28:75-84. 12047024
12. Covell NH Jackson CT Evans AC Essock SM Antipsychotic prescribing practices in Connecticut's Public Mental Health System: Rates of changing medications and prescribing styles Schizophr Bull 2002, 28:17-29. 12047017
13. Jerrell JM Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications Schizophr Bull 2002, 28:589-605. 12795493
14. Centorrino F Goren JL Hennen J Salavtore P Kelleher JP Baldessarini RJ Multiple versus single antipsychotic agents for hospitalized psychiatric patients: Case-control study of risks versus benefits Am J Psychiatry 2004, 161:700-706. 10.1176/appi.ajp.161.4.700 15056517
15. Faries D Ascher-Svanum H Zhu B Correll C Kane J Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics BMC Psychiatry 2005, 5:26. 1156914 15921508 10.1186/1471-244X-5-26
16. Ghaemi SN "All the worse for the fishes": Conceptual and historical background of polypharmacy in psychiatry Polypharmacy in psychiatry New York. Marcel Dekker, Inc Ghaemi SN 1 2002, 1-34.
17. Oepen Godehard Polypharmacy in schizophrenia Polypharmacy in psychiatry New York: Marcel Dekker, Inc Ghaemi SN 1 2002, 101-132.
18. Zhao Z Tunis SL Lage M Medication treatment patterns following initiation on olanzapine versus risperidone Clin Drug Invest 2002, 22:741-749. 10.2165/00044011-200222110-00003
19. Jaffe AB Levine J Antipsychotic medication coprescribing in a large state hospital system Pharmacoepidemiol Drug Saf 2003, 12:41-48. 10.1002/ pds.783 12616846
20. Correll CU Kane JM O'Shea D Razi K Malhotra AK Antipsychotic polypharmacy in the treatment of schizophrenia Schizophr Res 2003, (Suppl 1):37. 10.1016/S0920-9964(03)80107-X
21. Wang PF Zhao Z Comparison of olanzapine versus quetiapine in the treatment of hospitalized patients with schizophrenia Value in Health 2003, 6:355.
22. Gibson PJ Damler R Jackson EA Wilder T Ramsey J The impact of olanzapine, risperidone, or haloperidol on the cost of schizophrenia care in a Medicaid population Value in Health 2004, 7:22-35. 10.1111/ j.1524-4733.2004.71272.x 14720128
23. Correll CU Frederickson AM Kane JM Manu P Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007. 89:91-100. 10.1016/j.schres.2006.08.017 17070017
24. Yuzda MSK Combination antipsychotics: What is the evidence? J Inform Pharmacother 2000, 2:300-305.
25. Freudenreich O Goff DC Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations Acta Psychiatr Scand 2002, 106:323-330. 10.1034/j.1600-0447.2002.01331.x 12366465
26. Advokat C Dixon D Schnedier J Comaty JE Jr Comparison of risperidone and olanzapine as used under "real world" conditions in a state psychiatric hospital Prog Neuropsychopharmacol Biol Psychiatry 2004, 28:487-495. 10.1016/j.pnpbp.2003.11.015 15093956
27. Swanson JW Swartz MS Elbogen EB Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment Schizophr Bull 2004, 30:3-20. 15176758
28. Ascher-Svanum H Zhu B Faries D Lacro JP Dolder CR A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia J Clin Psychiatry 2006, 67:1114-1123. 16889456
29. Zhu B Tunis SL Zhao Z Baker RW Lage MJ Shi L Tohne M Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial Curr Med Res Opin 2005, 21:555-564,. 10.1185/030079905X38259 15899104
30. Citrome L Jaffe A Levine J Lindenmayer JP Dosing of quetiapine in schizophrenia: How clinical practice differs from registration studies J Clin Psychiatry 2005, 66:1512-1516. 16401150
31. Rupnow MF Greenspan A Kosik-Gonzalez C Zhu Y Garawabi G Stahl SM Use and cost of polypharmacy in schizophrenia: Data from a randomized double-blind study of risperidone and quetiapine Value in Health 2005, 8:399.
32. Stahl SM Antipsychotic polypharmacy, Part 1: Therapeutic opinion or dirty little secret? J Clin Psychiatry 1999, 60:425-426. 10453794
33. Stahl SM Antipsychotic polypharmacy: Squandering precious resources? J Clin Psychiatry 2002, 63:93-94. 11874226